Catalyst
Slingshot members are tracking this event:
Cidara (CDTX) Phase 2 RADIANT Data Evaluating Topical CD101 in Yeast Infection (Vulvovaginal Candidiasis VVC)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CDTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 21, 2017
Occurred Source:
http://ir.cidara.com/phoenix.zhtml?c=253962&p=irol-newsArticle&ID=2247615
Related Projects
- With Phase 2 Data Expected in Q1, Where Does Cidara's (CDTX) Topical CD101 Stand in the Antifungal Market for Yeast Infection (Vulvovaginal Candidiasis VVC)? CDTX Executed On: Jan 27, 2017 at 02:00 PM EST
Related Keywords
Phase 2, Radiant, Topical, Cd101, Vvc, Vulvovaginal Candidiasis
